[Translated article] AEDV BIOBADADERM Registry: 15 Year-Contribution to Psoriasis Therapy Safety

Area of Science:

• Dermatology
• Clinical Research
• Pharmacovigilance

Background:

• The BIOBADADERM registry was initiated in 2008 as a prospective cohort to monitor systemic therapies for psoriasis.
• Its primary goal is to assess the safety profile of novel systemic treatments in real-world clinical settings.

Observation:

• Over 15 years (2008-2023), the registry has accumulated substantial data on psoriasis management.
• This data has facilitated the publication of numerous research articles, contributing significantly to the field.

Findings:

• BIOBADADERM data complements clinical trial findings on treatment safety and efficacy.
• The registry provides crucial insights into patient populations often excluded from trials and less common clinical scenarios.
• Collaborations with other registries have enabled verification of findings in smaller cohorts.

Implications:

• The registry's long-term data collection enhances the understanding of long-term safety and efficacy of systemic psoriasis treatments.
• Findings support evidence-based clinical decision-making for dermatologists and healthcare providers.
• BIOBADADERM contributes to a more comprehensive safety profile of psoriasis therapies, benefiting a broader patient demographic.